Royalty Pharma plc · NASDAQ:RPRX

Royalty Pharma — Investor Presentation (November 2023)

7 slides from Royalty Pharma's investor presentation, November 2023

  1. Slide 1: Royalty Pharma

    Slide 1: Royalty Pharma

    ROYALTY PHARMA

  2. Slide 2: R&D co-funding for TEV-'749

    Slide 2: R&D co-funding for TEV-'749

    R&D co-funding for TEV-‘749 November 2023

  3. Slide 3: Forward Looking Statements

    Slide 3: Forward Looking Statements

    Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or

  4. Slide 4: TEV-'749 can fill a void among existing LAI treatments

    Slide 4: TEV-'749 can fill a void among existing LAI treatments

    TEV-‘749 can fill a void among existing LAI treatments 1 2 3 Teva’s TEV-‘749 in Phase 3 TEV-‘749 designed to LAI antipsychotics an for schizophrenia reduce the risk of PDSS attractive opportunity TEV-‘749 could offer the proven efficacy of Subcutaneous injection and polymer drug- LAI antipsychotics

  5. Slide 5: R&D partnership accelerates development of TEV-'749

    Slide 5: R&D partnership accelerates development of TEV-'749

    R&D partnership accelerates development of TEV-‘749 • R&D funding partnership with Teva on TEV-‘749 ▪ $100m R&D funding with $25m option for additional funding Royalty interest subject to mutual agreement on TEV-‘749 ▪ Entitled to low- to mid-single digit royalty on worldwide sales ▪ R&D funding pay

  6. Slide 6: TEV-'749 offers a potentially compelling profile

    Slide 6: TEV-'749 offers a potentially compelling profile

    TEV-‘749 offers a potentially compelling profile Zyprexa Relprevv(1) TEV-‘749 (Lilly’s LAI olanzapine) (Teva’s LAI olanzapine) Status Approved Phase 3 development (data H2 2024) Dosing frequency Every 2 or 4 weeks Once monthly Administration Intramuscular injection Subcutaneous injection Injection 1

  7. Slide 7: LAI antipsychotics an attractive market opportunity

    Slide 7: LAI antipsychotics an attractive market opportunity

    LAI antipsychotics an attractive market opportunity ~$4bn U.S. LAI market growing rapidly(1) ($ in millions) • Significant opportunity for conversion of treatment with oral olanzapine to TEV-‘749 if approved with favorable safety profile +16% CAGR • LAI antipsychotics are a ~$4bn U.S. market and gro

Source: company website

More decks from Royalty Pharma plc

All 68 Royalty Pharma decks